Skip to main content

Table 2 Safety and reported adverse events, occurring in two or more subjects, which were possibly, probably or definitely related to DPX-0907 treatment

From: First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients

Toxicity

Total No. of Patients

0.25 mL Group

1 mL Group

 

0.25 mL

1 mL

Grade 1

Grade 2

Grade 1

Grade 2

Grade 3

Injection site induration

11

9

6

5

3

5

1

Injection site erythema

8

10

6

2

5

4

1

Injection site pain

3

8

1

2

3

5

 

Injection site pruritis

3

2

3

 

1

1

 

Injection site warmth

2

2

1

1

1

1

 

Injection site hematoma

2

 

2

    

Injection site edema

1

4

1

 

2

2

 

Injection site discoloration

1

2

 

1

2

  

Injection site rash

1

1

1

  

1

 

Injection site urticaria

1

1

1

  

1

 

Injection site dry skin

1

1

1

 

1

  

Injection site ulceration

 

3

  

1

 

2*

Pain

3

1

2

1

 

1

 

Fatigue

2

 

1

1

   

Fever

1

2

 

1

1

1

 

Arthralgia

1

1

1

 

1

  

Myalgia

1

1

1

 

1

  

Anaemia

1

1

 

1

 

1

 
  1. *Appeared three or more weeks after of third injection and completely resolved.